- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06319911
AETOS Shoulder System
AETOS Shoulder System Post Market Clinical Investigation
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This study will confirm the safety and performance of the AETOS Shoulder System in anatomic and reverse TSA. Revisions will not be enrolled into this study.
The AETOS Shoulder System is manufactured by Smith & Nephew, Inc., 1450 Brooks Road Memphis, Tennessee 38116 USA, and has been 510k Cleared as of 07Jun2023; therefore, it is considered a post-market product and will be procured through normal commercial channels in the USA. The humeral stem is designed to be used for both Total Shoulder Arthroplasty (TSA) and reverse shoulder arthroplasty procedures. The humeral stems are designed with fins and a porous plasma coating to provide fixation within the proximal humeral metaphysis.
Study Type
Enrollment (Estimated)
Contacts and Locations
Study Contact
- Name: Karlie Morgan
- Phone Number: 5124967507
- Email: karlie.morgan@smith-nephew.com
Study Contact Backup
- Name: Tammy Clark, MPH
- Phone Number: 3512269585
- Email: tammy.clark@smith-nephew.com
Study Locations
-
-
California
-
San Francisco, California, United States, 94118
- Recruiting
- California Pacific Orthopedics
-
Contact:
- Katie Sheehi
- Phone Number: 415-668-8010
- Email: ksheehi@calpacortho.com
-
Principal Investigator:
- James Kelly, MD
-
-
Colorado
-
Denver, Colorado, United States, 80210
- Not yet recruiting
- Western Orthopaedics
-
Contact:
- Libby Mauter
- Phone Number: 303-321-1333
- Email: lmauter@western-ortho.com
-
Principal Investigator:
- Armand Hatzidakis
-
-
Georgia
-
Columbus, Georgia, United States, 31909
- Not yet recruiting
- Hughston Foundation
-
Contact:
- Cholly Minton
- Phone Number: 706-494-3330
- Email: cminton@hughston.com
-
Principal Investigator:
- Brent Ponce
-
-
Oregon
-
Bend, Oregon, United States, 97701
- Recruiting
- Center for Orthopedics and Neurosurgical Care
-
Contact:
- Cody Manriquez
- Phone Number: 541-420-0774
- Email: codymanriquez@gmail.com
-
Principal Investigator:
- Scott Jacobson, MD
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States, 19107
- Recruiting
- Rothman Institute
-
Contact:
- Brooke Olin
- Phone Number: 267-516-9393
-
Principal Investigator:
- Matthew Ramsey, MD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
Patients must meet all the following criteria to be included in the study:
- Patient is at least 18 years of age at the time of consent and skeletally mature.
Patient is undergoing a primary elective anatomic or reverse shoulder replacement surgery for one of the following indications:
- Rheumatoid arthritis, and/or
- Traumatic arthritis (Post Traumatic arthritis), and/or
- Non-inflammatory degenerative joint disease, and/or
- Correction of functional deformity.
- Patient is willing and able to accommodate all study-related procedures and visits detailed in the protocol & cooperate in the standard of care post-operative therapy.
- Patient is geographically stable and willing to return to the study site for all follow-up visits.
Patient has been adequately informed of risks and requirements of the study and is willing and able to provide informed consent for participation.
-
Exclusion Criteria:
Patients who meet any of the following criteria will not qualify for participation in the trial:
- Patient has a contraindication to AETOS.
- Patient is undergoing a revision shoulder replacement surgery including total or partial arthroplasty.
- Patient is indicated for a Hemiarthroplasty.
- Patient has traumatic injury or a fracture.
- Patient has uncontrolled diabetes with a hemoglobin A1C of 7.5 or greater.
- Patient has comorbidities/conditions that preclude proper healing/fixation of the implant.
- Patient has poor quality or insufficient bone stock to support the implant.
- Patient has poor bone quality where there could be considerable migration of the implant and/or a chance of fracture.
- Patient has rapid joint destruction, marked bone loss or bone resorption (e.g., severe osteoporosis).
- Patient has osteomalacia.
- Patient has muscular, neurologic, or vascular deficiencies that may compromise the outcome of the shoulder replacement surgery.
- Patient has a known sensitivity, allergic reaction, and/or known allergies to one or more of the implanted materials.
- Patient has a distant foci of infection which may spread to the implant site, active local or systemic infection, sepsis, or osteomyelitis.
- Patient has an elevation of sedimentation rate, elevation of WBC count, or marked shift in WBC differential count unexplained by other disease.
- If reverse shoulder arthroplasty, patient has a non-functional deltoid or external rotator muscles.
- If reverse shoulder arthroplasty, patient has a significant injury to the upper brachial plexus.
- If reverse shoulder arthroplasty, patient has paralysis of the axillary nerve.
- Patient is uncooperative, has a neurologic disorder and is not capable of following directions, or is a vulnerable subject per ISO 14155 (i.e., individuals who are unable to fully understand all aspects of the investigation that are relevant to the decision to participate, or who could be manipulated or unduly influenced as a result of a compromised position, expectation of benefits or fear of retaliatory response).
- Patient is pregnant or plans to become pregnant during the follow-up period.
- Patient has a Body Mass Index (BMI) of >35kg/m2 or a BMI that may compromise the outcome of the shoulder replacement surgery.
- Patient has anticipated activities which would impose high stresses on the implant and its fixation or has a high likelihood of a fall.
- Patient is a known smoker, vaper, alcohol abuser, or drug abuser within 180 days of consent.
- Patient has participated previously in this clinical trial and was withdrawn.
- Patient is participating in another device or drug trial or observational competitive study.
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Primary Anatomic
Those subjects who have the AETOS implanted in the Primary Anatomic configuration
|
The AETOS Shoulder System will be implanted into the right or left shoulder in the anatomic or reverse configuration
|
Primary reverse
Those subjects who have AETOS implanted in the Reverse configuration
|
The AETOS Shoulder System will be implanted into the right or left shoulder in the anatomic or reverse configuration
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Implant Survivorship
Time Frame: 2 years
|
Implant survivorship at 2 years post operatively defined as absence of device removal or revision of any component
|
2 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Implant Survivorship at 6 months, 1 year, 3.5 years and 5 years
Time Frame: 6 months, 1 year, 3.5 years, and 5 years
|
Implant Survivorship at 6 months, 1 year, 3.5 years, and 5 years defined as absence of device removal or revision of any component
|
6 months, 1 year, 3.5 years, and 5 years
|
Radiographic Assessment - Glenoid Migration/Subsidence
Time Frame: Day 0, 1 year, 2 years, and 5 years
|
Glenoid Component Migration / Subsidence collected post-surgery at day 0, 1 year, 2 years, and 5 years will be graded in accordance with the following definitions: 0. Absent: No evidence of glenoid component displacement ≥ 5 mm relative to the native bone stock. 1. Present: Presence of glenoid component displacement ≥ 5 mm relative to the native bone stock. |
Day 0, 1 year, 2 years, and 5 years
|
Radiographic Assessment - Glenoid Radiolucency
Time Frame: Day 0, 1 year, 2 years, and 5 years
|
Glenoid Component Radiolucency - antero-posterior (AP) collected post-surgery at day 0, 1 year, 2 years, and 5 years will be graded in accordance with the following definitions: 0. Absent: No evidence of radiolucency > 2 mm in width along the bone-implant / bone-cement interface in any zone. 1. Present: Presence of radiolucency > 2 mm in width along the bone-implant / bone-cement interface in one or more zones. |
Day 0, 1 year, 2 years, and 5 years
|
Radiographic Assessment - Humeral Radiolucency
Time Frame: Day 0, 1 year, 2 years, and 5 years
|
Humeral Component Radiolucency - AP collected post-surgery at day 0, 1 year, 2 years, and 5 years will be graded in accordance with the following definitions: 0. Absent: No evidence of radiolucency > 2 mm in width along the bone-implant interface in any zone. 1. Present: Presence of radiolucency > 2 mm in width along the bone-implant interface in one or more zones. |
Day 0, 1 year, 2 years, and 5 years
|
Radiographic Assessment - Humeral Migration/Subsidence
Time Frame: Day 0, 1 year, 2 years, and 5 years
|
Humeral Component Migration / Subsidence collected post-surgery at day 0, 1 year, 2 years, and 5 years will be graded in accordance with the following definitions: 0. Absent: No evidence of a change in position of the humeral component relative to the native bone stock ≥ 5 mm. 1. Present: Presence of a change in position of the humeral component relative to the native bone stock ≥ 5 mm |
Day 0, 1 year, 2 years, and 5 years
|
Radiographic Assessment - Humeral Head Centeredness
Time Frame: Day 0, 1 year, 2 years, and 5 years
|
Humeral Head Centeredness collected post-surgery at day 0, 1 year, 2 years, and 5 years will be calculated using the method described by Iannotti and Norris from the axillary view
|
Day 0, 1 year, 2 years, and 5 years
|
Radiographic Assessment - Bone Remodeling
Time Frame: Day 0, 1 year, 2 years, and 5 years
|
Bone Remodeling of the humerus collected post-surgery at day 0, 1 year, 2 years, and 5 years will be graded in accordance with the following definitions by Schnetzke et al.: 0. Absent: No evidence of humerus bone remodeling. 1. Present: Presence of one or more features of humerus bone remodeling.
|
Day 0, 1 year, 2 years, and 5 years
|
Radiographic Assessment - Glenohumeral Subluxation
Time Frame: Day 0, 1 year, 2 years, and 5 years
|
Glenohumeral Subluxation collected post-surgery at day 0, 1 year, 2 years, and 5 years will be will be derived from the Humeral Head Centeredness assessment using the following definitions, from Iannotti and Norris et al.: 0. Absent: Humeral Head Centeredness is ≤25%. 1. Present: Humeral Head Centeredness is >25%. |
Day 0, 1 year, 2 years, and 5 years
|
Radiographic Assessment - Device Condition: Anatomic
Time Frame: Day 0, 1 year, 2 years, and 5 years
|
Device Condition - Anatomic collected post-surgery at day 0, 1 year, 2 years, and 5 years will be graded in accordance with the following definitions: 0. Intact: No evidence of fracture, breakage, loosening, disassembly or migration of any of the components of the anatomic AETOS TSA. 1. Not Intact: Presence of fracture, breakage, loosening, disassembly or migration of one or more of the components of the anatomic AETOS TSA:
|
Day 0, 1 year, 2 years, and 5 years
|
Radiographic Assessment - Device Condition: Reverse
Time Frame: Day 0, 1 year, 2 years, and 5 years
|
Device Condition - Reverse collected post-surgery at day 0, 1 year, 2 years, and 5 years will be graded in accordance with the following definitions: 0. Intact: No evidence of fracture, breakage, loosening, disassembly or migration of any of the components of the reverse AETOS TSA. 1. Not Intact: Presence of fracture, breakage, loosening, disassembly or migration of one or more of the components of the reverse AETOS TSA:
|
Day 0, 1 year, 2 years, and 5 years
|
American Shoulder and Elbow Score (ASES)
Time Frame: 6 months, 1 year, 2 years, and 5 years
|
The ASES instrument is composed of 2 sections containing participant self-reported and clinician assessments.
The ASES score is a 0 to 100-point rating with a higher score indicating improvement in pain and function.
|
6 months, 1 year, 2 years, and 5 years
|
Constant Murley Score
Time Frame: 6 months, 1 year, 2 years, and 5 years
|
Constant-Murley Shoulder (CMS) scale assesses four aspects related to shoulder pathology; two subjective: pain and activities of daily living (ADL) and two objective: range of motion (ROM) and strength.
The subjective components can receive up to 35 points and the objective 65, resulting in a possible maximum total score of 100 points (best function).
Pain and ADL are answered by the subject; ROM and strength require a physical evaluation and are answered by the orthopaedic surgeon or the physiotherapist.
|
6 months, 1 year, 2 years, and 5 years
|
Simple Shoulder Test (SST)
Time Frame: 6 months, 1 year, 2 years, and 5 years
|
Series of 12 "yes" or "no" questions the patient answers about the function of the involved shoulder.
The answer to these questions provides a standardized way of recording the function of a shoulder before and after treatment.
|
6 months, 1 year, 2 years, and 5 years
|
Single Assessment Numeric Evaluation (SANE)
Time Frame: 6 months, 1 year, 2 years, and 5 years
|
The SANE is a simple, single-question, patient-based shoulder function assessment tool: ''How would you rate your shoulder today as a percentage of normal (0% to 100% scale with 100% being normal)?''
|
6 months, 1 year, 2 years, and 5 years
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Kolja Boese, Smith & Nephew, Inc.
Study record dates
Study Major Dates
Study Start (Estimated)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- AETOS 2022.04
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Shoulder Osteoarthritis
-
Indiana Hand to Shoulder CenterCTM BiomedicalActive, not recruitingShoulder Osteoarthritis | Osteoarthritis Shoulder | Glenohumeral OsteoarthritisUnited States
-
Lovisenberg Diakonale HospitalHaukeland University Hospital; Sykehuset Telemark; University Hospital, AkershusRecruitingShoulder Osteoarthritis | Arthroplasty, Replacement, ShoulderNorway
-
University Hospital, BrestUnknownShoulder Osteoarthritis | Arthropathy ShoulderFrance
-
FX Shoulder SolutionsRecruitingOsteoarthritis Shoulder | Rotator Cuff Syndrome of Shoulder and Allied Disorders | Fracture, ShoulderUnited States
-
Northwestern UniversityWithdrawnShoulder Osteoarthritis | Arthropathy ShoulderUnited States
-
FX Shoulder SolutionsRecruitingOsteoarthritis Shoulder | Rotator Cuff Syndrome of Shoulder and Allied Disorders | Fracture, ShoulderUnited States
-
Zealand University HospitalHvidovre University HospitalActive, not recruitingShoulder Pain | Shoulder Osteoarthritis | Shoulder ArthritisDenmark
-
Hospital for Special Surgery, New YorkRoyal Infirmary of EdinburghRecruitingKnee Osteoarthritis | Hip Osteoarthritis | Shoulder OsteoarthritisUnited States, United Kingdom
-
MaterialiseEnrolling by invitationOsteoarthritis of the Shoulder | Arthroplasty, Replacement, Shoulder | Glenoid CavityBelgium, Netherlands
-
Lawson Health Research InstituteRecruitingPain Management | Shoulder Arthroplasty | Shoulder OsteoarthritisCanada